UroGen Pharma

UroGen Pharma Ltd. is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases. It has developed RTGel reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. The firm's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Its approved product Jelmyto (mitomycin) for pyelocalyceal solution and investigational treatment UGN-102 (mitomycin) for intravesical solution are designed to ablate tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial cancer and low-grade non-muscle invasive bladder cancer respectively. The company was founded by Asher Holzer in 2004 and is headquartered in Princeton, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

UroGen Pharma reports solid Q2 performance and bullish on UGN-102

UroGen Pharma's Q2 performance showcased revenue growth for JELMYTO and promising data for UGN-102, supported by a successful public offering to drive future initiatives.
Despite challenges in revenue performance and market expectations, the company's strong commercialization plans and confidence in UGN-102's potential position it well for sustained growth.
Opportunities lie in upcoming NDA submission, product portfolio expansion, and strategic use of raised funds, indicating a positive outlook for UroGen Pharma's future trajectory.

UroGen Pharma excels in Q3 with strong revenue growth and promising trial results

UroGen Pharma's Q3 performance reflects robust revenue growth, promising trial outcomes, and strategic advancements in product development and commercialization.
While facing challenges in operational scalability and financial management, UroGen's strong performance, patent portfolio, and market readiness offer a solid foundation for future success.
Opportunities lie in the upcoming UGN-102 commercial launch, market expansion, and continued innovation, positioning UroGen for sustained growth and competitive advantage.
Overall, UroGen Pharma's Q3 earnings call highlights a positive trajectory with key milestones achieved and a clear strategic roadmap for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

UroGen Pharma Ltd. is a biopharmaceutical company, which engages in developing and commercializing innovative solutions that treat urothelial and specialty cancers. It also focuses on developing RTGel reverse-thermal hydrogel, a proprietary sustained release and hydrogel-based platform technology. The company was founded by Asher Holzer in 2004 and is headquartered in Princeton, NJ.

UroGen Is A Compelling Value With Recent FDA Approval

Ameresco

Cardtronics

eHealth

GW Pharmaceuticals

HCA Healthcare

Restaurant Brands

Whether or not a recovery is imminent, there are compelling stocks to buy, it’s just a matter of where you look for them.

7 Stocks to Buy for Their Double-Digit Growth Prospects

Shares of UroGen Pharma Ltd. gained 10.7% in premarket trading on Thursday after the Food and Drug Administration approved the company's urothelial cancer treatment the night before.

UroGen shares jump 10% on FDA approval of rare cancer treatment

UroGen (URGN) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

UroGen (URGN) Looks Good: Stock Adds 8.1% in Session

UroGen Pharma Ltd. (URGN) CEO Liz Barrett on Q4 2019 Results - Earnings Call Transcript

UroGen Pharma Ltd. (URGN) CEO Elizabeth Barrett on Q3 2019 Results - Earnings Call Transcript

Investors walked away from UroGen Pharma after an article was published by a short-seller, but clinical results appear to favor the company.

Are the Shorts Right About This Clinical-Stage Pharma?

UroGen Pharma Ltd. (URGN) CEO Liz Barrett on Q2 2019 Results - Earnings Call Transcript

CenturyLink

Encana

Three Stocks the World's Best Investors Are Buying Right Now

A major milestone gets closer with each passing day, but the stock seems to keep heading lower.

Here's Why the Best Is Yet to Come for UroGen Pharma

UroGen Pharma Ltd. (URGN) has been struggling lately, but the selling pressure may be coming to an end soon.

UroGen Pharma Sees Hammer Chart Pattern: Time to Buy?

Ally Financial

Noble Midstream Partners

Wall Street, and most investors who follow its lead, is overlooking this online bank, pharmaceutical company, and master limited partnership. Investors who are paying attention could score outsized gains by investing ahead of the crowd.

Three Stocks That Aren't on Wall Street's Radar

Axsome Therapeutics

Flexion Therapeutics

Axsome Therapeutics, Flexion Therapeutics, and UroGen Pharma gave investors reasons for excitement.

These 3 Small-Cap Healthcare Stocks Reported Big Updates This Month

UroGen Pharma Ltd. (URGN) CEO Liz Barrett on Q1 2019 Results - Earnings Call Transcript

Canada Goose Holdings

Pembina Pipeline

This Canadian midstream company, Canadian winter clothing manufacturer, and Israel-based pharma company could soon be making names for themselves in the U.S.

3 International Companies Making Waves in the U.S. Soon

This Israeli-based pharma company is poised to receive regulatory approval for its first product in the second half of 2019.

1 Under-the-Radar Healthcare Stock Wall Street is Overlooking

News for UroGen Pharma Stock (URGN)